Prognia
Drug Database
🇪🇺EU · EMAOpinionATC: L02BA05

Etcamah(camizestrant)

Breast Neoplasms

Marketing Authorisation Holder: AstraZeneca AB

INN: camizestrant

Indication

treatment of adults with locally advanced or metastatic breast cancer

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Etcamah — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.